9 Jan 2026
Work Package 2 of the SANGUINE project, completed over six months ago, marked a major scientific milestone by successfully identifying disease-specific epigenetic biomarkers for haematological malignancies. This work laid the foundation for the project’s diagnostic development by translating large-scale epigenetic data into clinically relevant tools.
The study analysed more than 400 blood samples from patients and age-matched healthy controls, enabling robust DNA methylation profiling in both whole blood and circulating cell-free DNA. By applying advanced statistical methods and machine-learning approaches, the consortium distilled these complex datasets into a high-confidence panel of biomarkers with strong discriminatory power.
These biomarkers now form the basis of the targeted, low-cost HemaChip microarray, which is being deployed across subsequent work packages. The completion of WP2 represents a critical step towards scalable clinical applications that support early detection, screening, and disease monitoring for haematological malignancies.